# NKMAXBio We support you, we believe in your research

# Recombinant human GITR/TNFRSF18 protein

Catalog Number: ATGP3319

#### PRODUCT INFORMATION

## **Expression system**

Baculovirus

#### **Domain**

26-162aa

#### **UniProt No.**

O9Y5U5

#### **NCBI Accession No.**

NP 004186.1

# **Alternative Names**

Tumor necrosis factor receptor superfamily member 18, Activation-inducible TNFR family receptor, Glucocorticoid-induced TNFR-related protein, CD357, AITR, GITR

### **PRODUCT SPECIFICATION**

## **Molecular Weight**

41.6 kDa (376aa)

### **Concentration**

0.5mg/ml (determined by absorbance at 280nm)

#### **Formulation**

Liquid in. Phosphate-Buffered Saline (pH 7.4) containing 10% glycerol

#### **Purity**

> 95% by SDS-PAGE

#### **Endotoxin level**

< 1 EU per 1ug of protein (determined by LAL method)

# **Tag**

hlgG-His-Tag

# **Application**

SDS-PAGE

# **Storage Condition**

Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

# **BACKGROUND**

# **Description**

TNFRSF18, also known as tumor necrosis factor receptor superfamily member 18 isoform 1, is receptor for TNFSF18. It seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. TNFRSF18 mediated NF-kappa-B activation via the



# NKMAXBIO We support you, we believe in your research

# Recombinant human GITR/TNFRSF18 protein

Catalog Number: ATGP3319

TRAF2/NIK pathway. Also, this protein reciprocally stimulated and activate intracellular signals regulating immune functions. In particular, GITR-driven T-cell co-stimulation was found to be the main mechanism by which the GITRL-GITR system contributes to tumor rejection and the development of autoimmune/inflammatory diseases. Recombinant human TNFRSF18, fused to hlgG-His-tag at C-terminus, was expressed in insect cell and purified by using conventional chromatography techniques.

# **Amino acid Sequence**


QRPTGGPGCG PGRLLLGTGT DARCCRVHTT RCCRDYPGEE CCSEWDCMCV QPEFHCGDPC CTTCRHHPCP PGQGVQSQGK FSFGFQCIDC ASGTFSGGHE GHCKPWTDCT QFGFLTVFPG NKTHNAVCVP GSPPAEP<LEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK HHHHHH>

#### **General References**

Lacal PM., et al. (2013) J. Pharmacol. Exp. Ther. 347:164-172. Xufre C., et al. (2013) Int. Immunol. 25:563-574. Shimizu J., et al. (2002) Nat. Immunol. 3:135-142.

#### **DATA**

#### **SDS-PAGE**



3ug by SDS-PAGE under reducing condition and visualized by coomassie blue stain.

